Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines

Biochemical Pharmacology

Volumn 70, Issue 5, 2005, Pages 725-732

  Azab, Samar S ^a   El Demerdash, Ebtehal ^a   Abdel Naim, Ashraf B ^a   Youssef, Ekram ^b   El Sharkawy, Nahla ^c   Osman, Abdel Moneim M ^b  

^a Ain Shams University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Cell cycle; Epirubicin; Multi drug resistance; P glycoprotein; Tamoxifen; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIRUBICIN; GLYCOPROTEIN P; SULFORHODAMINE B; TAMOXIFEN;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL LEVEL; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PLOIDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; TIME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; P-GLYCOPROTEIN; TAMOXIFEN;

EID: 23044506795     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.03.036     Document Type: Article

References (25)

1. F. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. Buzdar, and G. Hortobagyi Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond Oncologist 6 2001 133 146
2. J. Moscow, and K. Cowan Multi-drug resistance J Natl Cancer Inst 80 1988 14 20
3. J. Li, L. Xu, K. He, W. Guo, Y. Zheng, and P. Xia Reversal effects of nomegestrol acetate on multi-drug resistance in adriamycin-resistant MCF-7 breast cancer cell line Breast Cancer Res 3 2001 253 263
4. S.E. Salmon, W.S. Dalton, T.M. Grogan, P. Plezia, M. Lehnert, and D.J. Roe Multidrug-resistant myeloma: laboratory and clinical effects verapamil as a chemosensitizer Blood 78 1991 44 50
5. M. Ford, and W. Hait Pharmacology of drugs that alter multidrug esistance in cancer Pharmacol Rev 42 1990 155 199
6. F. Leonessa, M. Jacobson, B. Boyle, J. Lippman, M. McGarvey, and R. Clarke The effect of tamoxifen on the multi-drug resistance phenotype in human breast cancer cells: isobologram drug accumulation and gp-170 binding studies Cancer Res 54 1994 441 447
7. B. Fisher, and B. Sikic Clinical studies with modulators of multi-darug resistance Hematol Oncol Clin North Am 9 1995 363 382
8. H. Thomas, and H. Coley Overcoming multi-drug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein Cancer Control 10 2003 159 165
9. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer drug screening J Natl Cancer Inst 82 1990 1107 1112
10. M. Berenbaum What is synergy? Pharmacol Rev 41 1989 93 141
11. L. Seymour, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan The pharmacokinetics of polymer-bound adriamycin Biochem Pharmacol 39 1990 1125 1131
12. R. DeVincenzo, G. Scambia, P. Panici, A. Fattorossi, G. Bonanno, and C. Ferlini Modulatoy effect of tamoxifen and ICI 182 780 on adriamycin resistance in MCF-7 human breast cancer Int J Cancer 68 1996 340 348
13. A. Osman, M. Mohamed, A. Abdel-Wahab, and M. Sayed-Ahmed Modulation by verapamil of doxorubicin induced expression of multi-drug resistance gene (MDR-1/P-glycoprotein) in murine tumor cells J Egypt Natl Cancer Inst 12 2000 221 227
14. N. Stuart, A. Phillip, K. Harris, S. Houlbrook, J. Kirk, and E. Lien High dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines Br J Cancer 66 1992 833 839
15. D. Trump, S. Smith, P. Ellis, and M. Rogers High dose oral tamoxifen, a potential muti-drug resistance reversal agent: a phase I trial in combination with vinblastine J Natl Cancer Inst 84 1992 1811 1816
16. D. Ormrod, K. Holm, K. Goa, and C. Spencer Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer Drugs Aging 15 1999 389 416
17. D. Stacey, M. Hitomi, and G. Chen Infleunce of cell cycle and oncogene activity upon topoisomerase IIα expression and drug toxicity Mol Cell Biol 20 2000 9127 9130
18. Y. Kang, and R. Perry Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance Cancer Res 53 1993 3040 3045
19. E. Berman, M. Adams, R. Duiogou-Osterndorf, L. Godfrey, B. Clarkson, and M. Andreeff Effect of tamoxifen on cell lines displaying the multi-drug resistance phenotype Blood 77 1991 818 825
20. A. Ramu, D. Glaubiger, and Z. Fuks Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues Cancer Res 44 1984 4392 4395
21. P. Chaudhary, and I. Roninson Induction of multi-drug resistance in human cells by transient exposure to different chemotherapeutic drugs J Natl Cancer Inst 85 1993 632 639
22. C. Herzog, M. Tsokos, S. Bates, and A. Fojo Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists J Biol Chem 268 1993 2946 2952
23. S. Davies, C. Robson, and I. Hickson Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins J Biol Chem 263 1988 17724 17729
24. E. Schneider, J. Horton, C. Yang, M. Nakagawa, and K. Cowan Multi-drug resistance-associated protein gene over-expression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance Cancer Res 54 1994 152 158
25. T. Petit, M. Wiltb, M. Veltenc, R. Millond, J. Rodiere, and C. Borela Comparative value of tumor grade, hormonal receptors, Ki-67. HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy Eur J Cancer 40 2004 205 211